Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration (FDA) approved Brukinsa&trade; (zanubrutinib) capsules for the treatment of adults with <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/refractory-mantel-cell-lymphoma/">mantle cell lymphoma</a> (MCL) who have received at least one prior therapy.<h2>Tumor shrinkage with zanubrutinib</h2>The approval was based on results from a single-arm clinical trial that included 86 patients with <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/bloodline-familial-link-observed-with-blood-cancers/">MCL</a> who received at least one prior treatment. Among this cohort, 84% of patients had tumor shrinkage, with a median duration of response (DOR) of 19.5 months. This trial was supported by an additional single-arm study that included 32 patients, in whom 84% had tumor shrinkage, with a median DOR of 18.5 months.Common adverse events associated with zanubrutinib included decreased neutrophil count, decreased platelet count, upper respiratory tract infection, decreased white blood cell count, decreased hemoglobin, rash, bruising, diarrhea, and cough.The FDA said patients should be monitored for hemorrhage, signs and symptoms of infection, cytopenias, and cardiac arrhythmias during treatment.Patients should use sun protection when taking zanubrutinib due to the risk of other malignancies, including skin cancer. The FDA also advised that women who are pregnant or breastfeeding do not take zanubrutinib.The drugmaker, BeiGene Ltd, priced zanubrutinib at $12,935 for a 30-day supply, according to a report from Reuters.

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

FDA Approves Brukinsa™ for Previously Treated Mantle Cell Lymphoma

Oncology

The U.S. Food and Drug Administration (FDA) approved Brukinsa™ (zanubrutinib) capsules for the treatment of adults with mantle cell lymphoma (MCL) who have received at least ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe